Quarterly Activities Report & Appendix 4C (ASX Announcement)
Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.
Which ASX companies are resurrecting abandoned drugs? Part 3
"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.
Which ASX companies are resurrecting abandoned drugs? Part 3
DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review.
Breaking new ground via an oncology treatment tech venture
Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.
Starpharma and Medicxi to partner in Petalion Therapeutics, advancing dendrimer-drug cancer treatments
"Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics."
Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)
Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi
Investor Webinar Notification – Starpharma x Medicxi Partnership (ASX Announcement)
Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.